The assessment of Bayer HealthCare’s investigational drug regorafenib for the treatment of stomach tumoursis to be fast-tracked by US authorities for the treatment of stomach tumours Click here to read the report.

ASCO 2011 News reports that 36 months adjuvant Imatinib treatment for high risk GISTs improves recurrence-free survival (RFS) and even overall survival (OS). Click here to read the report.